Bleeding and thrombotic complications of kidney disease

S Pavord, B Myers - Blood reviews, 2011 - Elsevier
With the rising prevalence of kidney disease, clinicians are increasingly faced with concerns
about potential thrombotic and bleeding complications. Thrombotic risk, both arterial and …

How should we manage anaemia in patients with diabetes?

R Dikow, V Schwenger… - Nephrology Dialysis …, 2002 - search.ebscohost.com
Anaemia is an important component of diabetic nephropathy but only recently has it
attracted the attention of diabetologists and nephrologists. In diabetic patients, anaemia is …

[HTML][HTML] Phase 2 study of the factor XI antisense inhibitor IONIS-FXIRx in patients with ESRD

M Walsh, C Bethune, A Smyth, J Tyrwhitt… - Kidney international …, 2022 - Elsevier
Introduction Patients with end-stage renal disease (ESRD) requiring hemodialysis (HD)
have an increased risk of thrombotic events and bleeding. Antisense reduction of factor XI …

New insights in dialysis membrane biocompatibility: relevance of adsorption properties and heparin binding

J Chanard, S Lavaud, C Randoux… - Nephrology Dialysis …, 2003 - academic.oup.com
In the last 10 years, the concept of biocompatibility as applied to haemodialysis membranes
has gained a general clinical acceptance in light of the knowledge that the clinical …

Optimal anticoagulation strategy in haemodialysis with heparin-coated polyacrylonitrile membrane

S Lavaud, E Canivet, A Wuillai, H Maheut… - Nephrology Dialysis …, 2003 - academic.oup.com
Background. Binding of polycationic unfractionated heparin onto the modified AN69
polyacrylonitrile membrane, whose surface electronegativity has been neutralized by …

Detection and scoring of extracorporeal circuit clotting during hemodialysis

F Vanommeslaeghe, W Van Biesen, K François - Seminars in Nephrology, 2024 - Elsevier
Maintaining patency of the extracorporeal hemodialysis (HD) circuit is a prerequisite to
perform HD. Unfractionated heparin and low-molecular-weight heparins are the most used …

Systemic anticoagulation considerations in chronic kidney disease

WE Dager, TH Kiser - Advances in chronic kidney disease, 2010 - Elsevier
Anticoagulation therapy is commonly required in patients with chronic kidney disease for
treatment or prevention of thromboembolic disorders. Anticoagulant management plans can …

Biocompatibility assessment of haemodialysis membrane materials by proteomic investigations

L Pieroni, SL Mortera, V Greco, V Sirolli, M Ronci… - Molecular …, 2015 - pubs.rsc.org
The exposure of blood to an artificial surface such as the haemodialysis membrane results
in the nearly instantaneous deposition of a layer of plasma proteins. The composition of the …

Dialyzer performance during hemodialysis without systemic anticoagulation using a heparin-grafted dialyzer combined with a citrate-enriched dialysate: results of the …

K François, D De Clerck, A Tonnelier… - American Journal of …, 2022 - Elsevier
Rationale & Objective The EvoCit study was designed to evaluate performance of a heparin-
grafted dialyzer during hemodialysis with and without systemic anticoagulation. Study …

The clinical evaluation of low-dose heparin in haemodialysis: a prospective study using the heparin-coated AN69 ST membrane

J Chanard, S Lavaud, H Maheut, I Kazes… - Nephrology Dialysis …, 2008 - academic.oup.com
Abstract Background. The AN69 ST haemodialysis membrane, a new membrane resulting
from coating polyethyleneimine upon the polyacrylonitrile surface, binds heparin. In patients …